Bugging allergy; role of pre-, pro-and synbiotics in allergy prevention. 
Introduction
The epidemic rise in allergic diseases and asthma is inexorably linked to complex environmental and modern lifestyle changes. Urbanization and global decline of environmental biodiversity are directly implicated in changes in human commensal microbiota, which are critical for both normal immune maturation and subsequent immune function. While these global effects are likely to vary widely across both macro-scale geographic environments and micro-scale human microbial habitats, there is growing evidence that 'dysbiosis' is a major factor in the global increase in inflammatory non-communicable diseases including allergic disease. 1e3 The ecological pressures on microbial diversity are multifaceted and reflect changes in individual exposures such as nutritional patterns (increased processed foods, less fresh and fermented foods), sedentary indoor living (vitamin D insufficiency, reduced nature relatedness and exposure to environmental biodiversity) as well as the wider social and economic drivers of 'dysbiotic drift '. 4e6 Thus while it is important to develop strategies for individuals to restore personal biodiversity for disease prevention, as is the subject of this review, it is equally important to address the fundamental drivers of dysbiosis and nutritional supplements must be viewed in this broader ecological context. 7 The establishment of commensal microbiota in the gastrointestinal tract is critical to provide the tolerogenic microenvironment necessary for optimal development of both innate and adaptive immunity. 8 Adverse influences on early colonization may have long-lasting consequences, exemplified by numerous examples of early compositional and functional differences in early life gut microbiota that precede the onset of eczema and asthma. 9e20 While it has been logical to explore the role of probiotics, 21 prebiotics 22 and combinations of these (synbiotics) ( Table 1) , to favorably modulate gut microbiota, it is also important that such interventions are considered in tandem with other strategies that address the perinatal practices and environmental factors that are contributing to dysbiosis in the first place. Thus, although this review is concerned with the specific impact of prebiotics and probiotics in the perinatal setting, we underscore that, even if effective, such products are only one aspect of the solutions.
The importance of gut microbiota establishment in the development of oral tolerance and immune competence
The ambient conditions during initial antigen exposure, typically when the gastrointestinal immune system is still immature, are important for the success of oral tolerance. The mechanisms that initiate and maintain tolerance to dietary antigens are still being defined, however early microbial exposure appears essential in promoting an appropriate regulatory milieu during this period of dynamic development (Fig. 1) . 23e25 Delivery method, antibiotic usage, breastfeeding, perinatal environmental factors and numerous factors that influence maternal microbiota in pregnancy and lactation are important in this early colonization processes e many of these now implicated in altered patterns of early colonization which may predispose to allergy and possible other early onset NCDs. 3 For example, reduced gut microbial diversity and an elevated Enterobacteriaceae/Bacteroidaceae ratio in early life appears associated with an increased risk of developing food sensitization and atopic eczema. 13, 14, 26, 27 Moreover, gut microbiota composition at age 3e6 months was recently associated with milk allergy resolution at 8 years of age. 28 New insights into how the gut microbiota influences food allergy have been provided by experimental animal models, clearly demonstrating that absence of microbiota during a short time interval in early life can result in defects in immune regulation. 29 While this extreme microbial depletion does not resemble the more subtle disruptions observed in humans, it nonetheless indicates that the high microbial content in the gut is crucial for sustaining the homeostatic host-microbiome relationship and preventing intestinal inflammation and allergies by inducing mucosal IgA and regulatory T-cell (Treg) responses. 8, 25, 29, 30 The main mechanisms of induction of oral tolerance are mediated by Foxp3þ Treg, known to mediate suppressive reactions thus avoiding excessive immune activation. 24 IgA, as the most abundant mucosal immunoglobulin isotype, is important in the establishment of composition of intestinal microbiota 31 and may reinforce oral tolerance by strengthening the mucosal barrier function. 32 In line with this hypothesis, aberrant IgA responses to the gut microbiota during infancy were recently observed to precede allergy development during the first seven years of life. 33 The lack of intestinal microbiota in germ free mice is associated with a Th2-skewed immune response, with enhanced IgE responses to food antigens, and/or a defect in mounting proper regulatory T-cell responses. 8, 34, 35 Thus, an early exposure to microbial symbionts occurring during certain time windows of developmental plasticity, potentially also during the prenatal period (either directly or indirectly through maternal immunomodulation), might be beneficial in preventing development of Th2-mediated allergic disease. 36 Preliminary evidence that reduced fecal diversity of Bacteroidetes in pregnancy is associated with increased risk of atopic eczema in their young children gives further support for a Table 1 Definitions.
Probiotics "live microorganisms, which when administered in adequate amounts confer a health benefit on the host" 21 Prebiotics "substrate that is selectively utilized by host microorganisms conferring a health benefit" 22 
Synbiotics
The combination of probiotics and prebiotics Fig. 1 . Possible prenatal and postnatal mechanisms for induction of oral tolerance. Pro-and prebiotics administration during pregnancy can influence mother's gut microbiome potentially resulting in transmission of tolerogenic mediators (such as regulatory cytokines, antibodies and growth factors) through the placenta instructing foetal immune system development. Following vaginal delivery, the newborn's gut acquires the maternal vaginal (including Lactobacillae and Bifidobacterium) and gut (Bacteroides) microbiome favouring initial microbial colonization. Postnatally, oral administration of pro-and prebiotics together with breastfeeding and high-fibre diet might support ongoing intestinal colonization by symbiotic bacteria (including Clostridium spp. and Bacteroides fragilis) sustaining the homeostatic host-microbiome relationship. This might in turn prevent intestinal inflammation and decrease susceptibility to food allergies by inducing mucosal IgA and regulatory T-cell (Treg) responses.
role of maternal microbiota in this process. 17 In addition to induc- Deficiency in genetic elements that are coding for microbial sensors in mice, such as Toll like receptor 4 (TLR4) and CD14 (enhancing the detection of bacterial LPS by TLR4) also increases susceptibility to food allergies. 41, 42 Food allergy-prone mice, with a gain-of-function mutation in the IL-4 receptor, exhibit an altered gut microbiota signature, reflected by changes in the abundance of bacterial families Lachnospiraceae and Lactobacillaceae. 43 In this food allergy model, transplanted healthy infant microbiota, comprising mainly of Bifidobacterium and Bacteroides, had a protective role on sensitization and cow's milk allergy development in mice despite altered T-cell responses in the ileum. This could be due to the capability of the above-mentioned bacteria to restore Treg cell responses over time in the ileum. 35, 43 Other indigenous commensal bacteria can stimulate innate signalling pathways in the host by direct cell-to-cell interactions or through secretion of short chain fatty acids (SCFA), regulated by high-fiber diet. Studies have shown that bacterially produced SCFA can regulate both the proportions and functional properties of intestinal Treg cells 44e46 and inhibit pro-inflammatory responses by intestinal macrophages. 44, 47 Intervention studies, elucidating the effect of high-fiber prebiotics in modulating the intestinal human microbiota for prevention or treatment of food allergy is a logical strategy that should be assessed in future research.
Primary prevention studies using probiotics, prebiotics and synbiotics
The first studies targeting the gut microbiota for allergy prevention focused on the potential benefits of probiotics, with more recent studies examining prebiotics and synbiotics in this context.
Probiotics and eczema
The preventative effects of probiotics have been evaluated in randomized controlled trials (RCTs) 48e63 (Table 2 ) and the majority used eczema or IgE-associated eczema as the primary outcome. Most studies used single strains of lactobacilli and bifidobacteria, or their combination (Table 2) . Long-term follow-up data is available for less than half of these studies 64e74 while many others are still under way ( Table 2 ). The most recent meta-analyses reported a benefit of probiotics for primary prevention of eczema, but no significant effects on any other allergic outcomes. 75, 76 In the metaanalysis of Zuccotti et al., 76 which included 17 studies (4755 children), there was a significantly lower relative risk (RR) for eczema in those treated with probiotics compared with placebo (RR 0.78; 95% CI: 0.69e0.89). Notably, the benefit was most evident when a mix of probiotic strains was administered (RR; 0.54 95% CI, 0.43e0.68). Cuello-Garcia et al. 75 included 29 studies in their metaanalysis, though some of these were reports from the same study population but at different occasions of follow-up. In their metaanalysis, they also examined the effects of both timing of probiotics and the method of administration. There was a benefit of probiotics for eczema reduction (follow-up period until 2 years of age) when administered in the last trimester of pregnancy (RR 0.71; 95% CI, 0.60e0.84), when administered during breast-feeding (RR 0.57; 95% CI, 0.47e0.69), or when administered to infants and/or mothers (RR, 0.80; 95% CI, 0.68e0.94). No significant effect on eczema was reported when probiotics were administered solely to the infant (RR, 0.83; 95% CI, 0.58e1.19). The authors assessed the certainty in the evidence based on the Grading of Recommendation Assessment Development and Evaluation (GRADE) approach, and found it to be low or very low due to "risk of bias, inconsistency and imprecision of results, and indirectness of available research". 75 Peldan et al. 73 recently reported long-term follow up data on eczema from the largest probiotic study conducted to date, results that were not available for inclusion in the 2015 meta-analyses. 75, 76 They found the life-time prevalence of eczema until 10 years of age to be reduced in the probiotic group that received a combination of 4 probiotic strains ( examinations including Scoring Atopic Dermatitis (SCORAD) assessment, the long-term follow-up data relied solely on questionnaire ereported data, which could be a limitation. Nevertheless, the study gives further support for long-term preventative effects on eczema of specific probiotics.
Effects of probiotics beyond the skin-atopy and food allergy
As discussed, most studies were designed to evaluate effects of probiotics on early manifestations of allergic disease, e.g. eczema.
Most studies also included measures of sensitization and in a metaanalysis from 2016, which included 17 trials (2947 infants), 77 pooled analysis showed that the combination of pre-and postnatal probiotic treatment decreased the risk of "any" sensitization (RR 0.78; 95% CI 0.66e0.92). This was most evident when probiotics were given in pregnancy to the mother and then to the infant postnatally (RR 0.71; 95% CI 0.57e0.89). A combined prenatal plus postnatal probiotic administration also reduced the risk of food sensitization (RR 0.77; 95% CI 0.61e0.98). In their conclusion, the authors underscored a call for studies examining the effects of probiotics for prevention of food allergy and that the studies should use objective clinical assessments, such as food challenges. 77 
Probiotics and respiratory allergies
There is very little evidence for a role of probiotics in the prevention of respiratory allergies including asthma, wheeze and rhinitis. In the meta-analysis by Azad et al. 78 which included 9 trials (3257 children) the RR of asthma in children treated with probiotics was 0.99 (95% CI 0.81e1.21) and the RR of wheeze was 0.97 (95% CI 0.87e1.09), (9 trials, 1949 children) . Similarly, in the follow-up study by Peldan et al., 73 there was no benefit of probiotic treatment on parental questionnaire-reported asthma until 10 years of age. In another recent report, there was no preventative effect of probiotics on asthma in follow-up (ranging from 5 years to 10e15 years of follow-up) of a pooled population of probiotic RCTs 74 (Table 2) . Intriguingly, the recent study by Peldan et al. 73 found questionnaire-reported allergic rhinoconjunctivitis to be more prevalent in children at 5e10 years of age who had previously received a probiotic combination compared with placebo. A similar finding of increased allergic rhinitis in probiotic-treated children was reported previously by Kalliom€ aki and coworkers. 65, 79 ( Table 2) . As it is difficult to distinguish between allergic and viral rhinitis, particularly when relying on parent-reported data, a causal relationship between probiotics and increased allergic rhinitis/ rhinoconjunctivitis cannot be concluded.
In all, the current collected evidence does not support the use of probiotics for primary prevention of allergic outcomes other than eczema. On the other hand, there is insufficient evidence to exclude this possibility either, as most conducted RCTs have not been adequately powered to examine the effects of less prevalent allergic outcomes e.g. asthma and food allergy. 80 For these reasons, there is still need for carefully designed and adequately powered RCTs to examine the effects of probiotics for prevention of food allergy and respiratory allergies.
Prebiotics, synbiotics and allergic outcomes
Human milk oligosaccharides (HMOs) are the third largest fraction in human milk and they serve as substrates for specific microbes to modulate infant gut microbiota composition. 81 They are sometimes referred to as "natural prebiotics" and until very recently, they have not been commercially available. No studies to date have been designed to assess the allergy-preventive effects of HMOs. Although much less structurally diverse than HMOs, specific prebiotics e.g. galactooligosaccharides and/or fructooligosaccharides have been added to infant formula and examined as an allergy-preventive measure. In a systematic review of prebiotics for allergy prevention from 2016 82 meta-analysis (5 studies, 1313 infants) reported no difference in eczema (RR: 0.57, 95% CI: 0.30e1.08). The two studies (249 infants) that reported early respiratory outcomes were included in a meta-analysis that found reduced infant asthma or recurrent wheeze (RR: 0.37, 95% CI: 0.17e0.80) in infants that had received prebiotics. Only one study examined the risk of food allergy and found a reduced risk (RR: 0.28, 95% CI 0.08e1.00) in prebiotic-treated infants. 82 The effects of synbiotics for eczema prevention have been assessed in two RCTs. 54, 83 Meta-analysis of these studies (2 studies, 1320 children) reported the pooled relative risk ratio (RR) to be 0.44 (95% CI, 0.11 to 1.83; P ¼ 0.26). 84 In their meta-analysis, the Kukkonen "synbiotic" study 54 was included. This study has also been included in many meta-analyses of probiotics. 80 Collectively, there is need for well-designed studies assessing the effects of both prebiotics and synbiotics for allergy prevention.
Effects on immunological outcomes
Pre-and postnatal probiotic supplementation has been hypothesized to provide microbial stimuli aiding the maturation of wellregulated innate and adaptive immune responses during infancy that protect from early infection, while minimizing inappropriate inflammatory responses to allergens. 80, 85, 86 While infants have capacity to initiate Th1 responses, this appears to be relatively suppressed under the influence of the Th-2 promoting hormonal milieu of pregnancy 87e92 which reflects the close immunological interaction between the mother and her offspring during pregnancy. In some studies this neonatal Th2-skewing is even more marked in infants who later develop allergy 90,96e98 and there is evidence that these children fail to attenuate their perinatal propensity for Th2 responses as their immune system matures. 90,91,95,99e102 Appropriate development of regulatory T cell responses 91, 103 and maturation of Th1-like responses 90, 104 are characteristic as the more mature immune phenotype develops during childhood. Also, establishment of an adequate mucosal barrier function, e g by increasing secretory IgA production during infancy, seems important to counteract allergic responses. 29,33,105e107 It is logical to propose that pre-and postnatal probiotic supplementation could be one strategy to shape appropriate development of systemic and mucosal immunity when these signal are otherwise deficient. Immune modulatory effects of probiotic administration have been characterized during infancy in several of the randomized double blind placebo-controlled allergy prevention trials. In line with Th1 maturation promoting effects, a higher ratio of anti-CD3/ CD28 induced IFN-g/IL-4 mRNA expression was observed at 13 months of age after feeding Lactobacillus paracasei ssp paracasei F19, as compared with placebo, during weaning. 63 Moreover, preand postnatal supplementation with a mixture of Bifidobacterium bifidum, Bifidobacterium lactis and Lactococcus lactis was associated with reduced levels of the Th2 cytokines IL-5 and IL-13 at 3 months of age after anti-CD2/CD28 stimulation of whole blood cultures. 58 Lower cat allergen induced IL-5 and IL-13 production by peripheral blood mononuclear cells has also been observed in 6-montholds after pre-and postnatal Lactobacillus reuteri supplementation compared with a placebo group, although these children subsequently also showed reduced cat allergen induced IFN-g levels at 2 years of age. 108 In the same cohort, detection of L. reuteri in fecal samples, collected during the first week, was associated with lower circulating levels of the Th2-associated chemokines CCL22 and CCL17 and higher Th1-associated CXCL11 levels at 6 months. 90 However, comparison of chemokine levels were not significantly different, suggesting potential dose-dependent immune modulatory effects depending on variations in colonization. 90 Interestingly, in a placebo-controlled intervention trial comparing two different probiotic strains, Lactobacillus rhamnosus supplementation 2e5 weeks before delivery was associated with increased cord blood IFN-g levels whereas B. lactis supplementation was not. 109 Furthermore, only the L. rhamnosus strain (and not the B. lactis strain) showed eczema preventative effects. 56 Thus, immune modulatory effects vary with dose, strain and also treatment duration and timing. This may also explain why Th1 maturation promoting effects by probiotics have not been consistently observed in all studies.
110e112
Beneficial effects of probiotics may also be mediated through improved mucosal barrier function and integrity e potentially through effects on IL-22, which induces epithelial cell proliferation and enhancing production of mucus and antimicrobial peptides. 113 In a recent study increased proportions of IL-22 producing Th cells were observed in 3-month-old infants after maternal pre-and postnatal supplementation with a mixture of L. rhamnosus, Lactobacillus acidophilus and B. lactis compared with the placebo group. 112 Even though these children had similar proportions of PMA/ionomycin-induced Th1, Th2 and Th17 cells, changes in barrier function could be of biological significance in reducing mucosal inflammation and the risk of sensitization. Secretory IgA also plays an important role in enhancing mucosal barrier function. 31, 114 Pre-and postnatal supplementation with a mix of L. rhamnosus GG and LC705 and B. breve Bb99 and Proprionibacterium freudenreichii ssp. shermani JS plus prebiotic galactooligosaccharides tended to be associated with increased fecal IgA levels at 3 months of age 106 and increased plasma IgA levels were observed at 6 months of age in the active compared with the placebo group. 115 Increased colostrum IgA levels were observed after L. rhamnosus as well as B. lactis administration, in comparison with placebo treatment, 109 while IgA levels in colostrum were not affected by probiotic treatment in other allergy intervention trials. 116, 117 Regulatory T cells can induce IgA isotype switching via secretion of IL-10 and TGF-b. 114 Defining regulatory T cells in vitro can be difficult, however, 118, 119 and clear effects of probiotic treatment on circulating regulatory T cell populations in infants have not been observed. 111, 112, 120 However, reduced responsiveness to allergens 108 and TLR2 ligands 121 in vitro after pre-and postnatal L. reuteri supplementation may indirectly indicate enhancement of regulatory responses. Further studies are required to delineate the effects of pre-and postnatal probiotic supplementation on development of systemic and mucosal immunity.
Effects on gut microbiota
Pre-and postnatal probiotic supplementation has been hypothesized to beneficially affect gut microbiota composition. 3, 122 When collating the findings from the different randomized double blind placebo controlled allergy prevention trials, it is important to recognize the impact of varying methodologies used to characterize the gut microbiota composition. 3, 123, 124 Findings from traditional culture based methods are difficult to compare to studies based on next generation sequencing. However, even within next generation sequencing studies, there is another layer of variability introduced by the choice of sequencing platform, DNA extraction, primer design, sequencing depth, data processing etc which may also hamper comparability. 3, 123, 124 While there is some evidence for a bifidogenic effect of probiotic supplementation in allergy prevention trials, 125, 126 this has not been consistently observed. 58, 61 Generally, more global gut microbiota diversity promoting effects have not been observed in the early in life probiotic allergy prevention trials, using next generation sequencing methodologies after pre-and postnatal supplementation with L. reuteri, 13 L. rhamnosus, L. acidophilus and B. lactis 127 or B. bifidum, B. lactis and L. lactis. 128 There is insufficient data using next generation sequencing methodologies in prebiotic studies for allergy prevention in the perinatal period. In several studies the specific probiotic strains used in supplement studies have been detected in feces only during the administration period, but not after the intervention, 56,71,127e129 suggesting only transient colonization. Long-term follow up of gut microbiota development has been performed only in one allergy prevention study so far. 128 In that study, gut microbiota development was followed to the age of six years, and only minor and short term differences were observed between the probiotic and placebo groups, as determined using 16Se23S rDNA interspace region based profiling. 128 Another important aspect that only has been evaluated in one study so far, 130 is whether the eczema preventative effects of the probiotic supplementation are dependent on the intrinsic gut microbiota composition in early infancy. Interestingly, high abundance of Bifidobacterium dentium in infant fecal samples collected at 10 days of age was associated with a lack of eczema preventive efficacy by maternal pre-and postnatal supplementation with a mixture of L. rhamnosus, L. acidophilus and B. lactis.
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To summarize, while probiotic strains may be transiently detected during the supplementation period in most studies, clear gut microbial diversity promoting effects early in life have not been observed. This does not exclude changes in the metabolic activity of resident microbiota 131 and/or other biologically relevant effects on host immune interactions. Effects on gut microbiota composition are likely to vary with dose, strain and also treatment duration and timing, in line with the reported differences for immunomodulatory and clinical outcomes. Long-term effects of pre-and postnatal probiotic supplementation on gut microbiota development need to be investigated in further studies.
Challenges and current recommendations
We recently discussed the challenges when analyzing the results of conducted studies and meta-analyses in this research area, and these include large heterogeneity and lack of harmonization in both probiotic and prebiotic studies. 80 80 On the other hand, the GRADE-based guidelines from the World Allergy Organization (WAO) recommend probiotics for the primary prevention of eczema in pregnancy and during breastfeeding when there is high risk of allergic disease (based on a positive family history) and in high risk infants. 137 WAO also recommends prebiotics in the primary prevention of allergy in non-exclusively breastfed infants. 82 In accordance with recent meta-analyses and other expert bodies, the WAO guideline panel recognized that the recommendations on both probiotics and prebiotics are conditional and based on very low quality evidence. In their document, conditional recommendations refer to the notion that most patients may want to follow the proposed recommendation, whereas other may not. 80, 82, 137 Clinicians need to help families in making decisions according to their preferences. 80 To date, these general recommendations cannot yet be translated into specific practice recommendations on the most effective strains, dosages or optimal duration of treatment. 
Summary and perspectives
Recent meta-analyses demonstrate a preventative effect of probiotics on eczema but not any other allergic manifestations. In their GRADE-based recommendation the WAO guideline panel suggests using probiotics in pregnant and breastfeeding women and in infants when there is high risk of allergy based on allergic heredity. Compared with probiotic studies, prebiotic studies for allergy prevention are fewer. Meta-analyses report a benefit of prebiotics on early respiratory outcomes and food allergy and WAO now recommends prebiotics in non-exclusively breastfed infants. To replicate the encouraging results we propose collaborative interdisciplinary multicentre studies with harmonized protocols and outcomes. 3, 8, 80, 141 Ultimately, such efforts could lead to specific practice guidelines on probiotics, prebiotics and synbiotics in the prevention of allergic diseases and asthma-and possibly other conditions. In the meantime, this should not delay interim advice to both practitioners and the public about the importance of the early colonization including the role of healthy nutrition, breastfeeding, introduction of complementary foods and nature-relatedness. Nor should it be a substitute for addressing the other economic, environmental, societal and lifestyle factors which are contributing to dysbiotic drift at both an individual and a planetary level. Diseases of 'dysbiosis' (which literally translates to 'life in distress') can be viewed as a human barometer of social and ecological dysbiosis on a global scale. 6 This underscores the inexorable links between human and environmental health and our responsibility to address these wider issues in the quest to improve human health. Dysbiosis cannot be achieved without addressing these up-stream drivers. 6 Conflict of interest CEW has received honoraria from Abbott Nutrition, Nutricia/Danone, Thermo Fisher Scientific and Nestl e Nutrition, and receives royalties from UptoDate. SLP has received honoraria from Abbott Nutrition, Nutricia/Danone, Nestl e Nutrition and Health World, consultancy fees from Bayer Pharmaceuticals and royalties from UptoDate. MCJ has received funding and honoraria for lectures from BioGaia AB, consultant fees and travel support from Nutricia/Danone. MD declares no conflict of interest.
